Eli Lilly & Co. (NYSE:LLY) - Page 2

Short Sellers Can’t Make Up Their Minds on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

FDA Delivers Big Rheumatoid Athritis Disappointment for Eli Lilly and Incyte

Big Pharma and Big Biotech sometimes live and die by actions out of the U.S. Food and Drug Administration (FDA). For Eli Lilly and Co. (NYSE: LLY) and Incyte Corp. (NASDAQ: ...
Read Full Story »

Top Dividend Pharmaceutical Stocks Safe Bet for Rest of 2017

One thing that crept on the radar screen last week is that after eight years of a bull market, five of which are of the secular variety, after the S&P 500 ...
Read Full Story »

Short Sellers Run for Cover From Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Analysts Keep Stacking Up Higher Targets and Expectations for Eli Lilly

Eli Lilly and Co. (NYSE: LLY) is one of the better pharmaceutical stocks, as far as performers in 2017 top picks at JPMorgan. Its shares were last seen up 17% ...
Read Full Story »

Major Pharma Short Sellers Couldn’t Make Up Their Minds Before Failed Trump Health Care Vote

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Back Off Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Prescription drugs

Why Short Sellers Are Making a Massive Bet in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Pair of dice

Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Prescription drugs

How Eli Lilly Earnings Won Big on New Drug Sales

Eli Lilly and Co. (NYSE: LLY) released its fourth-quarter earnings report before the markets opened on Tuesday. The company said that it had $0.95 in earnings per share (EPS) and $5.76 ...
Read Full Story »
100 dollar bills

Top 7 Earnings Reports to Look For Tuesday

As January is coming to a close, the fourth-quarter earnings season is beginning to slow, but it's not over yet. 24/7 Wall St. has put together a preview of some of ...
Read Full Story »
Prescription drugs

Short Sellers Run for Cover From Major Pharma

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Jon's friends

Wednesday’s Top Biopharma Winners

The third week of the New Year is halfway over, and a few biopharma companies made massive runs on the day. The health care sector was in trouble over the ...
Read Full Story »
bigger fish

What Eli Lilly Gets With CoLucid Acquisition

Eli Lilly and Co. (NYSE: LLY) has announced it has reached an agreement to acquire CoLucid Pharmaceuticals Inc. (NASDAQ: CLCD) in an all-cash transaction for $46.50 per share, or about ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: American Express, JPMorgan, Netflix, Nordstrom, Twitter and Many More

Stocks were indicated to open lower on Tuesday after a three-day weekend. Despite the Dow Jones Industrial Average not yet cracking the elusive 20,000 mark, there is a path for the ...
Read Full Story »